Epithelial-Mesenchymal Transition regulators (EMT regulators)

Epithelial-Mesenchymal Transition (EMT) regulators comprise a complex network of proteins, including transcription factors (e.g., Snail, Twist, ZEB) and signaling molecules (e.g., TGF-beta, Wnt), that orchestrate the conversion of stationary epithelial cells into mobile mesenchymal cells (PubMed PMID: 30310041). This process is fundamental to embryonic development and physiological wound healing but is frequently co-opted by cancer cells to drive metastasis, immune evasion, and resistance to conventional therapies (PubMed PMID: 29551271). In the context of oncology, these regulators are viewed as critical therapeutic targets, though they represent a pathway rather than a single molecule (Nature Reviews Cancer). Current pharmacological efforts primarily target upstream activators like the TGF-beta receptor to indirectly suppress the EMT program (Clinical Cancer Research). However, because EMT regulators play essential roles in normal tissue maintenance, their systemic inhibition carries risks of toxicity, such as impaired healing and skin-related adverse events (Journal of Clinical Oncology). Monitoring biomarkers like the loss of E-cadherin and the gain of Vimentin is standard for assessing EMT status in clinical and preclinical settings (UniProt).

Other names

EMT-inducing transcription factorsEMT-TFsMesenchymal transition factorsEMT-related factors

Inhibition of upstream signaling pathways (e.g., TGF-beta receptor antagonism) or direct modulation of transcription factor activity to prevent the transition of epithelial cells into a mesenchymal phenotype.